<DOC>
	<DOCNO>NCT00686439</DOCNO>
	<brief_summary>We conduct pilot study effectiveness adalimumab inflammatory osteoarthritis .</brief_summary>
	<brief_title>Adalimumab Inflammatory Osteoarthritis</brief_title>
	<detailed_description>This 20 patient pilot open-label study efficacy adalimumab inflammatory osteoarthritis knee . Primary endpoint 12 week primary outcome OARSI responder index .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patient 40 year age old . If female , patient either childbearing potential , defined postmenopausal least 1 year surgically sterile ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) , childbearing potential practice one follow method birth control : condom , sponge , foam , jelly , diaphragm intrauterine device ( IUD ) contraceptive ( oral parenteral ) three month prior study drug administration ) , vasectomized partner , total abstinence sexual intercourse If patient female childbearing potential , result serum pregnancy test perform Screening , prior first dose adalimumab , must negative . Patient diagnosis OA index knee accord American College Rheumatology criterion , include radiological evidence OA ( KellgrenLawrence grade 2 3 ) . Patient continual pain least 6 month prior inclusion study . This include pain persist despite conventional treatment , define one follow medication take daily precede month : acetaminophen ( 2 4 gram per day ) maximum tolerate recommended dos NSAID , acetaminophen/codeine combination ( i.e . Tylenol No 2 , 3 , 4 ) take least 3 time daily Patient daily knee pain month precede study enrolment . Patient sum pain score 125400mm ( visual analog scale ) WOMAC pain subscale index ( symptomatic ) knee . Patient clinical evidence knee effusion index ( symptomatic ) knee Screening Baseline . Subject history allergic reaction significant sensitivity constituent Adalimumab . Patient history proven systemic arthritis rheumatoid arthritis . Patient concurrent medical arthritic condition could confound evaluation index joint e.g . posttraumatic secondary form knee OA Patient predominant patellofemoral disease</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>osteoarthritis</keyword>
	<keyword>adalimumab</keyword>
	<keyword>mri</keyword>
</DOC>